Comparative evaluation of salivary hepatocyte growth factor in smokers and non‐smokers with chronic periodontitis

Abstract

Salivary HGF levels positively correlated with PD progression and smoking status. A significant reduction in HGF levels was seen after NSPT. Thus, within limits, it can be suggested that HGF plays a role in PD progression and can be used as a diagnostic biomarker to detect disease activity. Salivary HGF levels could also be useful to monitor response to periodontal therapy.

The impact of smoking on non‐surgical periodontal therapy: A systematic review and meta‐analysis

“…WDPD was the highest when AlAhmari et al (2019) was omitted (−0.25, CI [−0.37, −0.13]). WDCAL was the lowest when Guru et al (2018) were omitted (−0.23, CI: [−0.42, −0.04]). WDCAL was the highest when the data set of AlAhmari et al (2019) was omitted (−0.15, CI: [−0.24, 0.07]).…”

“…The significant negative influence of smoking is confirmed by several studies (Ardais et al, 2014;Eltas & Orbak, 2012;Hughes et al, 2006;Jin et al, 2000;Palmer et al, 1999;Wan et al, 2009). However, some studies did not find such significant negative impact of smoking on clinical outcomes following non-surgical periodontal therapy (Feres et al, 2015;Guru et al, 2018;Preshaw et al, 2013;Türkoğlu et al, 2016).…”

“…Since the difference in mean baseline PD was significantly associated with PD reduction difference after non-surgical treatment between the groups, the included articles were sub-grouped into (a) When the two studies, Guru et al (2018) and Preber et al (1995), with the shortest follow-up (1 month) were excluded, both PD reduction (WDPD: −0.37, CI [−0.56, −0.19]) and CAL gain (WDCAL: −0.23, CI [−0.42, −0.04]) in the S were still significantly lower than in the NS. None of the data sets appeared to significantly affect the pooled PD or CAL differences between two groups (Appendix S5).…”

“…Although several studies agreed upon worse periodontal disease and less favourable response to periodontal therapy in smokers (Boström et al, 1998; Heasman et al, 2006; Preber & Bergström, 1990; Tonetti et al, 1995), some studies suggested otherwise (D’Aiuto et al, 2005; Guru et al, 2018; Preshaw et al, 2013). A prospective cohort study (Guru et al, 2018) revealed no significant differences between smokers and non‐smokers in PD (respective mean of 1.96 and 1.98 mm) and CAL (respective mean of 1.32 and 1.29 mm) changes one month after full‐mouth scaling and root planning. Additionally, several other studies did not find significant differences between smokers and non‐smokers regarding outcomes of surgical treatments (Machtei et al, 1998), including soft tissue grafting (Harris, 1994) and dental implant placement (Weyant, 1994).…”

Saliva proteomics updates in biomedicine

“…The levels of hepatocyte Growth Factor (HGF), a multifunctional cytokine, were found to positively correlate with periodontitis progression and smoking habits. A significant reduction in HGF levels was observed after non-surgical periodontal therapy suggesting that HGF could be used to monitor response to periodontal therapy [44]. Vasoactive Intestinal Peptide (VIP), and Neuropeptide Y (NPY) in saliva (but interestingly not in serum) could potentially be gender-specific salivary biomarkers for periodontitis, regardless of psychological stress [45].…”